Genetic Testing for Breast Cancer Prevention and Treatment

Overview of Genetic Testing

Genetic tests for breast cancer prevention and treatment have become standard practice in many modern medical facilities. A recent review emphasizes the significance of genetic testing in this field, outlining the circumstances under which these tests should be conducted, the reasons for their use, and the methodologies involved.

Prevalence of Breast Cancer

Breast cancer is one of the most commonly diagnosed cancers in the United States, affecting approximately one out of every 800 women. A notable portion of these cases is attributed to inherited mutations that significantly elevate the risk of developing breast cancer and other cancer types.

Key Genetic Mutations

Among the most prevalent mutations that contribute to inherited breast cancer are those affecting the BRCA1 and BRCA2 genes. These mutations account for about 30% of all inherited breast cancer cases. Both genes encode proteins that play a crucial role in safeguarding the genome against harmful mutations that could lead to cancer initiation or progression.

Additional Genetic Factors

In addition to BRCA1 and BRCA2, mutations in genes such as TP53 and PTEN may also contribute to certain inherited breast cancer cases. However, the clinical syndromes associated with these latter mutations are linked to an increased risk of various other cancer types. Unlike BRCA1 and BRCA2, TP53 and PTEN mutations do not specifically drive breast cancer but instead influence tumor development across a broader range of tissues.

Importance of Genetic Testing

The genetic predisposition for breast cancer can be identified through standard genetic testing. A positive result may be crucial for implementing risk-reduction strategies, which could include enhanced surveillance, preventive chemotherapy, or even mastectomy. However, these tests should be reserved for specific cases due to medical, psychological, and economic considerations.

Guidelines for Genetic Testing

To assist general surgeons in determining which cases necessitate genetic testing, a recent review published in JAMA Surgery provides a comprehensive overview of widely accepted guidelines for the use of genetic tests. The authors begin by discussing the appropriate circumstances for conducting BRCA1 and BRCA2 preventive genetic screening tests. Medical advisory committees generally agree that a personal or family history of BRCA1/2 mutations, particularly in cases of early-onset breast cancer, warrants further investigation.